McKee Michael D, Wild Lisa M, Schemitsch Emil H, Waddell James P
Division of Orthopaedics, Department of Surgery, St. Michael's Hospital, and the University of Toronto, Toronto, Ontario, Canada.
J Orthop Trauma. 2002 Oct;16(9):622-7. doi: 10.1097/00005131-200210000-00002.
We sought to evaluate the use of a bioabsorbable, tobramycin-impregnated bone graft substitute (calcium sulfate alpha-hemihydrate pellets) in the treatment of patients with infected bony defects and nonunions.
STUDY DESIGN/METHODS: Twenty-five patients (15 male and 10 female, mean age 43 years (range 27-69 years) requiring surgical debridement of culture-positive long bone infection (16 with associated nonunion) were entered into an ongoing consecutive, prospective clinical trial. Involved bones included the tibia ( 15), femur ( 6), ulna ( 3), and humerus ( 1). All defects were posttraumatic in origin, and each patient had had previous surgery at the involved site (mean 4.3 surgeries; range 1-8 surgeries). The duration of infection ranged from 4 months to 20 years (mean 43 months). According to the Cierny-Mader classification system, there was 1 stage I (medullary osteomyelitis), 6 stage III (localized osteomyelitis), and 18 stage IV (diffuse osteomyelitis) lesions. There were 4 normal (A) hosts and 21 locally and/or systemically compromised (B) hosts. Mean bone defect/void was 30.5 cm (range 3-192 cm ).
Mean follow-up was 28 months (range 20-38 months). Radiographically, pellets were resorbed at a mean of 2.7 months postoperatively. Infection was eradicated in 23 of 25 patients (92%). Isolated bony defects healed in all nine patients without further treatment. Fourteen of 16 patients with nonunion achieved union, although nine required autogenous bone grafting. Union was achieved in five of seven nonunion patients treated with bone graft substitute in isolation. Complications included refracture (three), recurrence of infection (two), persistent nonunion (two), and superficial wound necrosis (one). Eight patients developed sterile draining sinuses that healed upon radiographic resorption of the pellets.
In patients with posttraumatic osteomyelitis, the bone graft substitute was effective in eradicating bone infection in 23 of 25 patients. Isolated bony defects healed reliably (nine of nine) following addition of bone graft substitute alone. The role of the bone graft substitute in isolation in the treatment of nonunion is unclear at present.
我们旨在评估一种可生物吸收的、含妥布霉素的骨移植替代物(硫酸钙α-半水合物颗粒)在治疗感染性骨缺损和骨不连患者中的应用。
研究设计/方法:25例患者(15例男性和10例女性,平均年龄43岁(范围27 - 69岁))因培养阳性的长骨感染(16例伴有骨不连)需要手术清创,进入一项正在进行的连续前瞻性临床试验。受累骨骼包括胫骨(15例)、股骨(6例)、尺骨(3例)和肱骨(1例)。所有缺损均为创伤后所致,且每位患者在受累部位均曾接受过手术(平均4.3次手术;范围1 - 8次手术)。感染持续时间为4个月至20年(平均43个月)。根据Cierny - Mader分类系统,有1例I期(骨髓炎)、6例III期(局限性骨髓炎)和18例IV期(弥漫性骨髓炎)病变。有4例正常(A)宿主和21例局部和/或全身功能受损(B)宿主。平均骨缺损/空洞为30.5 cm(范围3 - 192 cm)。
平均随访28个月(范围20 - 38个月)。影像学上,颗粒在术后平均2.7个月被吸收。25例患者中有23例(92%)感染被根除。9例孤立性骨缺损患者未经进一步治疗均愈合。16例骨不连患者中有14例实现骨愈合,尽管9例需要自体骨移植。7例仅接受骨移植替代物治疗的骨不连患者中有5例实现骨愈合。并发症包括再次骨折(3例)、感染复发(2例)、持续性骨不连(2例)和浅表伤口坏死(1例)。8例患者出现无菌性引流窦,在颗粒影像学吸收后愈合。
在创伤后骨髓炎患者中,骨移植替代物在25例患者中的23例有效根除了骨感染。仅添加骨移植替代物后,孤立性骨缺损可靠愈合(9例中的9例)。目前,骨移植替代物单独在治疗骨不连中的作用尚不清楚。